Therapeutic Antibodies

Therapeutic antibodies
#Alzheimer's #Antibodies #Cancer #Covid-19 #Engineered antibodies #Immunology #Janssen #Monoclonal antibodies #Rare disease #Therapeutic Antibodies

Podcast: Where is the innovation in the therapeutic antibody market?

This is the latest episode of the free DDW narrated podcast, titled “Where is the innovation in the therapeutic antibody market?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases… Read More

#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Drivers and challenges in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Monoclonal antibody
#Antibodies #Drug discovery #Immunology / Virology & Vaccines #Therapeutic Antibodies

Antibody therapies: A core technology of the past, present, and the future

Jeff Fischer, President of Longhorn Vaccines & Diagnostics, discusses the evolution of antibody therapies from early serum treatments to targeted monoclonal antibodies, their impact on disease prevention and treatment, and the growing acceptance of antibody-based alternatives to traditional vaccines. Antibody therapy has been used to prevent and treat disease for over… Read More

#Exclusive Content

#Acute inflammatory conditions #Financing #GPCRs #Maxion Therapeutics #Therapeutic Antibodies

Maxion Therapeutics raises $72m to advance KnotBody pipeline

Maxion Therapeutics has raised $72 million in an oversubscribed Series A Financing to advance its antibody-based KnotBody drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases.  The financing was led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and… Read More

#Business & Investment #News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Therapeutic antibody innovation

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar highlights innovation in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

#Antibody drug conjugate (ADC) #Big pharma #Drug development #Drug discovery #Heidelberg Pharma #Takeda #Therapeutic Antibodies

A global overview of therapeutic antibody development

DDW’s Megan Thomas takes a wide-angle look at the sector and speaks to experts and thought leaders about their predictions for therapeutic antibodies in 2025. Clinical advancements Marcelo Freire, Vice President of Global Medical Affairs, Therapeutic Area Head of Gastroenterology at Takeda, comments on monoclonal antibodies (mAbs) from a gastro… Read More

#Business & Investment #Exclusive Content

Bispecific antibodies
#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

Download the Article: The discovery and evolution of antibody formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This Article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent F1P HF as an alternative strategy for isolating… Read More

#News

#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

The Discovery and Evolution of Antibody Formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent™ F1P HF as an alternative strategy for isolating next-generation… Read More

#Resources

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

What are the drivers and challenges in therapeutic antibody discovery?

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies

What are the drivers and challenges in therapeutic antibody discovery?

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry. You will hear from Aron Knickerbocker, CEO of Aulos Bioscience, and Martin… Read More

Webinar date:
Sponsored by Bio-Rad
#Webinars

#Therapeutic Antibodies

Digital Article: The Discovery and Evolution of Antibody Formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent™ F1P HF as an alternative strategy for isolating next-generation… Read More

#Digital Articles

#Antibodies #Bispecific Antibodies #Interview #Oncology #Therapeutic Antibodies

Dual-targeted antibody innovations for cancer treatment

David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, speaks to Megan Thomas about innovation in therapeutic antibody development, in the context of the company’s accelerated development of a novel PD1/VEGFR2 bifunctional antibody planned to enter the clinic in 2025, designed as a dual-pathway, single agent, IgG therapy targeting… Read More

#Cancer Research #Exclusive Content

Antibodies
#Antiverse #Artificial intelligence (AI) #Collaboration #GPCRs #Nxera Pharma #Therapeutic Antibodies

Partners set out to design GPCR-targeted antibodies using AI

A new multi-target partnership aims meet unmet need by designing antibodies for G-protein coupled receptors (GPCRs). The collaboration will combine Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries’, with Nxera’s NxWave platform for GPCR target selection, validation and structural determination. Read More

#Business & Investment #News

Weight loss concept
#Mouse models #Obesity #Skye Bioscience #Therapeutic Antibodies #Weight loss

Significant weight loss with novel CB1-inhibiting antibody

Skye Bioscience has announced preliminary data from a diet-induced obesity (DIO) model in mice, in which its CB1-inhibiting antibody, nimacimab, achieved dose-dependent weight loss of up to 16% compared to vehicle. Skye developed a DIO model using a transgenic mouse expressing the human CB1 receptor… Read More

#News